Market Overview

J.P. Morgan Reiterates Overweight Rating on Pfizer

Share:
Related PFE
Bayer's Latest Stage 2 Trial Could Be A Boon For Shares
S&P 500 Index Futures Trading Lower In Choppy, Volatile Session
Should You Sell GE, AT&T, Pfizer? Check Weekly Charts (Investor's Business Daily)

In a report published Monday, J.P. Morgan & Co. reiterated its Overweight rating on Pfizer (NYSE: PFE).

J.P. Morgan noted, “Maintain Overweight rating. We see Pfizer offering an attractive mix of 1) inexpensive valuation (11x '13 EPS), 2) an approaching nearterm new product cycle with 3) a high FCF/dividend yield, and 4) limited earnings risk, in our view. We see Pfizer's business unit divestitures as potentially unlocking significant value and anticipate continued high levels of capital return to shareholders, including what we forecast will be $10+ billion of share repurchase in 2013.”

Pfizer closed on Friday at $24.89.

Latest Ratings for PFE

DateFirmActionFromTo
Aug 2015JefferiesMaintainsBuy
Jun 2015JefferiesInitiates Coverage onOverweight
Jun 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (PFE)

Get Benzinga's Newsletters